Cerus (NASDAQ: CERS) had its price target increased by Wedbush from $4.00 to $5.00 in a research report sent to investors on Monday morning. The firm currently has an outperform rating on the stock.

Several other analysts have also recently commented on the stock. Analysts at MLV Capital raised their price target on shares of Cerus from $5.00 to $7.50 in a research note to investors on Monday. They now have a buy rating on the stock.

Shares of Cerus traded up 1.32% during mid-day trading on Monday, hitting $4.215. Cerus has a 52 week low of $2.68 and a 52 week high of $4.53. The stock’s 50-day moving average is currently $3.34. The company’s market cap is $234.6 million.

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.